B-MYCIN Cream

Indication:

Treatment of impetigo, ecthyma and other lacalised primary bacterial skin infection with a gram-negative component and also for secondary bacterial infections complication other pre-existing dermatoses.

Dosage and administration: 

Apply a thin layer to the affected area twice daily.

Hypersensitivity to any of B-mycin components.

Treatment with gentamicin has produced transient irritation (erythema and pruritus) that usually did not require discontinuance of treatment.

Reported adverse reactions with the use of topical corticosteroids include: Burning, itching, irritation, dryness, hyppigmentation and allergic contact dermatitis.

(See Special Precaution)

1. If irritation or sensitization develops with the use of B-mycin cream, treatment should be discontinued.

2. Since safety of topical corticosteroid use in pregnant women has not been established, drugs of this class should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

3. B-mycin cream is not recommended for use in nursing mothers.

4. Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression and to exogenous corticosteroid effects than mature patients because of greater absorption due to a large skin surface area to body weight ratio.

5. HPA axis suppression, Cushing's syndrome, lineargrowth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absense of response to ACTH stimulation. Manifestations of intracranial hypertension include a bulging fontaelle, headaches and bilateral papilledema.

6. Systemic absorption of topical corticosteroids wil be increased if extensive body surface areas are treated or if the occlusive technique is used. Suitable precautions should be taken uner these conditions or when long-term use is anticipated, particularly in infants and children.

7. Use of topical antibiotics occasionallly allows overgrowth of nonsusceptible organism, including fungi. If this occurs or if irritation, sensitization or superinfection develops, treatment with gentamicin should be discontinued and appropriate therapy instituted.

Treatment of impetigo, ecthyma and other localised primary bacterial skin infection with a gram-neative component and also for secondary bacterial infections complicating other pre-existing dermatoses.

1. Betamethasone diprorionate topically produce prompt, marked and proloned anti-inflammatory,antipruritic and vasoconstrictive effects. Gentamicin is a bactericidal against a broad spectrum of common skin pathogens to which inflammatory skin disorders may be susbeptible.

2. Corticosteroids diffuse across cell membranes and complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, bind to DNA (chromatin), and stimulate transcription of messenger RNA (mRNA) and subsequent protein synthesis ofvarious inhibitory enzymes responsible for the anti-inflammatory effects of topical corticosteroids.

3. Bacteria susceptible to the action of gentamicin include sensitive strains of Streptococci, Staphylococcus aureus, and the gram-negative bacteria Pseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Proteus vulgaris and Klebsiella pneumoniae.